ClinicalTrials.gg
RecruitingNCT06403735Updated May 8, 2024

A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of QLC1101 in Non-small Cell Lung Cancer, Colorectal Cancer and Pancreatic Cancer, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Carcinoma, Non-Small-Cell Lung by Qilu Pharmaceutical Co., Ltd. — 5 open to participants now, 8 under way, 3 of them phase 3. Carcinoma, Non-Small-Cell Lung · Qilu Pharmaceutical Co., Ltd..

Planned enrollment
6th of 13
250 · median 176
Started
2024
the only one that year
Phase 1
3 of 14
3 open now
Registered
11th of 14
by date

Among the 14 studies in Carcinoma, Non-Small-Cell Lung by Qilu Pharmaceutical Co., Ltd., this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 1, and was the 11th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 14 studies in Carcinoma, Non-Small-Cell Lung by Qilu Pharmaceutical Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Carcinoma, Non-Small-Cell Lung by Qilu Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

QLC1101 is a selective reversible inhibitor of KRAS G12D, with the dosage form of capsules and administration route of oral administration. In the first-in-humans (FIH) study, the sponsor will explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of QLC1101 in subjects with advanced solid tumors harboring a KRAS G12D mutation. The FIH study includes dose escalation, PK expansion, and efficacy expansion.

03

Conditions studied

  • Non-small Cell Lung Cancer
  • Colorectal Cancer
  • Pancreatic Cancer
  • Solid Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with confirmed advanced ( or unresectable) solid tumors harboring a KRAS G12D mutation. Sign the ICF.
  2. Those who fail or are unable to tolerate standard treatment, lack standard treatment, or refuse to receive standard treatment;
  3. Those who are able to swallow and retain oral medication and must not have any gastrointestinal abnormality that may alter absorption;
  4. Subjects who have at least one documented by computed tomography (CT) and/or magnetic resonance imaging (MRI) as confirmed by the investigator per the v1.1 criteria.
  5. PS score: 0 or 1;
  6. Expected survival time ≥ 3 months;
  7. Adequate organ function at screening:

Exclusion criteria

Exclusion Criteria:

  1. Previously treated with inhibitors against KRAS G12D mutation;
  2. The period of time prior to the first dose of product should be at least 28 days from previous treatment or at least 5 half-lives
  3. Known immediate or delayed or idiosyncratic reaction to the ingredients of the preparation used in the trial;
  4. Presence of other active malignant tumors in addition to primary tumors;
  5. Presence of serious lung diseases at screening;
  6. gastrointestinal disorders or other conditions that seriously interfere with drug absorption;
  7. Severe hereditary or acquired hemorrhagic diathesis or coagulation disorders;
  8. Complicated with clinically significant cardiovascular and cerebrovascular disorders;
  9. History of hematopoietic stem cell transplantation or organ transplantation (except corneal transplantation);
  10. Presence of known mental disorders, epilepsy, dementia, or alcohol and drug abuse that may affect the compliance with study requirements;
  11. the investigator determines that participation in the study is not in the best interest of the subject.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    QLC1101

    patients with advanced solid tumors harboring a KRAS G12D mutation were administrated with QLC1101 orally in a total of 6 dose groups at 100,200,400,600,900, and 1200 mg BID

    Drug: QLC1101

Interventions

  • QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    Subjects in this phase will be treated with single oral administration of QLC1101, observed for 4 days, and if tolerant, treated with repeated oral administration of QLC1101 twice daily for 21 consecutive days. After completing the DLT observation (the 25 days after the first dose as the DLT observation period), the subject will continue to receive repeated-dose treatment of Cycle 2 and subsequent cycles.

    Time frame: 25 days after the first dose

  2. MTD (or MAD)

    the maximum tolerated dose (MTD) or maximum administered dose (MAD, if MTD fails to be determined) of QLC1101 monotherapy

    Time frame: 1 year

  3. RP2D

    the recommended phase II dose of QLC1101 monotherapy

    Time frame: 1.5 years

Secondary outcomes

  1. Preliminary efficacy endpoints

    Objective response rate (ORR)

    Time frame: 3 years

  2. Preliminary efficacy endpoints

    overall survival (OS)

    Time frame: 3 years

07

Study locations

1 of 5 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for May 2026, 25 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 25 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2024
First posted
May 8, 2024
StartActual
Apr 25, 2024
Primary completionEst.
May 31, 2026
CompletionEst.
Apr 30, 2027
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06403735
Responsible party
Sponsor
First posted
May 8, 2024
Start date
Apr 25, 2024
Primary completion
May 31, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
May 8, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KRAS G12D Inhibitor QLC1101

Start the discussion